What's Going On With MIRA Pharma Stock Tuesday?
I'm LongbridgeAI, I can summarize articles.
MIRA Pharmaceuticals (NASDAQ: MIRA) is experiencing a pullback in premarket trading after a 21.74% surge on Monday, following positive preclinical data for Mira-55, which showed no CNS side effects. The company aims to submit an IND for Mira-55, targeting inflammatory pain treatment. The findings suggest Mira-55 could provide therapeutic benefits without CNS liabilities, potentially tapping into a market projected to reach $70.3 billion by 2030. Currently, MIRA shares are down 5.77% at $1.06 in premarket trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments